Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
7
CCM Quote, Financials, Valuation and Earnings
Last price:
$3.58
Seasonality move
:
0.82%
Day range:
$3.41 - $3.59
52-week range:
$3.19 - $10.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.30x
P/B ratio:
--
Volume:
5.9K
Avg. volume:
6.6K
1-year change:
-24.35%
Market cap:
$15.1M
Revenue:
$53.4M
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CCM
Concord Medical Services Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | -- | -- | -- |
|
YI
111, Inc.
|
$514.9M | -- | -4.26% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$122.7M | -$0.42 | 17.43% | -30.7% | $43.42 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CCM
Concord Medical Services Holdings Ltd.
|
$3.48 | -- | $15.1M | -- | $0.00 | 0% | 0.30x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.77 | $4.00 | $15.7M | -- | $0.00 | 0% | 0.45x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
$10.42 | -- | $21.2B | 29.93x | $0.00 | 0% | 7.86x |
|
YI
111, Inc.
|
$8.18 | -- | $70.9M | -- | $0.00 | 0% | 0.04x |
|
ZLAB
Zai Lab Ltd.
|
$20.04 | $43.42 | $2.2B | -- | $0.00 | 0% | 4.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CCM
Concord Medical Services Holdings Ltd.
|
273.84% | -1.505 | 77.28% | 0.19x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | -0.389 | 55.28% | 0.19x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.263 | 12.91% | 11.22x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
5.93% | -0.126 | -- | 1.98x |
|
YI
111, Inc.
|
-42.73% | -1.247 | 17.3% | 0.41x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | -0.192 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CCM
Concord Medical Services Holdings Ltd.
|
-- | -- | -7.49% | -19.78% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | 7.16% | 7.53% | -- | -- |
|
YI
111, Inc.
|
$24.9M | -$302.8K | -15.3% | -26.11% | -0.07% | $5.3M |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Concord Medical Services Holdings Ltd. vs. Competitors
-
Which has Higher Returns CCM or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to Concord Medical Services Holdings Ltd.'s net margin of -353.92%. Concord Medical Services Holdings Ltd.'s return on equity of -19.78% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital CCMConcord Medical Services Holdings Ltd.-- -- $727.8M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About CCM or CASI?
Concord Medical Services Holdings Ltd. has a consensus price target of --, signalling upside risk potential of 244.83%. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 422.81%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Concord Medical Services Holdings Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Concord Medical Services Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CCMConcord Medical Services Holdings Ltd.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is CCM or CASI More Risky?
Concord Medical Services Holdings Ltd. has a beta of -1.213, which suggesting that the stock is 221.26% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.412%.
-
Which is a Better Dividend Stock CCM or CASI?
Concord Medical Services Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Concord Medical Services Holdings Ltd. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCM or CASI?
Concord Medical Services Holdings Ltd. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Concord Medical Services Holdings Ltd.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Concord Medical Services Holdings Ltd.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concord Medical Services Holdings Ltd. is 0.30x versus 0.45x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCMConcord Medical Services Holdings Ltd.0.30x -- -- -- CASICASI Pharmaceuticals, Inc.0.45x -- $3.1M -$10.9M
-
Which has Higher Returns CCM or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to Concord Medical Services Holdings Ltd.'s net margin of --. Concord Medical Services Holdings Ltd.'s return on equity of -19.78% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital CCMConcord Medical Services Holdings Ltd.-- -- $727.8M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About CCM or SVA?
Concord Medical Services Holdings Ltd. has a consensus price target of --, signalling upside risk potential of 244.83%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Concord Medical Services Holdings Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Concord Medical Services Holdings Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CCMConcord Medical Services Holdings Ltd.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is CCM or SVA More Risky?
Concord Medical Services Holdings Ltd. has a beta of -1.213, which suggesting that the stock is 221.26% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.394%.
-
Which is a Better Dividend Stock CCM or SVA?
Concord Medical Services Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Concord Medical Services Holdings Ltd. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios CCM or SVA?
Concord Medical Services Holdings Ltd. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. Concord Medical Services Holdings Ltd.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, Concord Medical Services Holdings Ltd.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concord Medical Services Holdings Ltd. is 0.30x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCMConcord Medical Services Holdings Ltd.0.30x -- -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns CCM or WXXWY?
WuXi Biologics (Cayman), Inc. has a net margin of -- compared to Concord Medical Services Holdings Ltd.'s net margin of --. Concord Medical Services Holdings Ltd.'s return on equity of -19.78% beat WuXi Biologics (Cayman), Inc.'s return on equity of 7.53%.
Company Gross Margin Earnings Per Share Invested Capital CCMConcord Medical Services Holdings Ltd.-- -- $727.8M WXXWYWuXi Biologics (Cayman), Inc.-- -- $6.6B -
What do Analysts Say About CCM or WXXWY?
Concord Medical Services Holdings Ltd. has a consensus price target of --, signalling upside risk potential of 244.83%. On the other hand WuXi Biologics (Cayman), Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Concord Medical Services Holdings Ltd. has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe Concord Medical Services Holdings Ltd. is more attractive than WuXi Biologics (Cayman), Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCMConcord Medical Services Holdings Ltd.0 0 0 WXXWYWuXi Biologics (Cayman), Inc.0 0 0 -
Is CCM or WXXWY More Risky?
Concord Medical Services Holdings Ltd. has a beta of -1.213, which suggesting that the stock is 221.26% less volatile than S&P 500. In comparison WuXi Biologics (Cayman), Inc. has a beta of -0.062, suggesting its less volatile than the S&P 500 by 106.225%.
-
Which is a Better Dividend Stock CCM or WXXWY?
Concord Medical Services Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WuXi Biologics (Cayman), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Concord Medical Services Holdings Ltd. pays -- of its earnings as a dividend. WuXi Biologics (Cayman), Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCM or WXXWY?
Concord Medical Services Holdings Ltd. quarterly revenues are --, which are smaller than WuXi Biologics (Cayman), Inc. quarterly revenues of --. Concord Medical Services Holdings Ltd.'s net income of -- is lower than WuXi Biologics (Cayman), Inc.'s net income of --. Notably, Concord Medical Services Holdings Ltd.'s price-to-earnings ratio is -- while WuXi Biologics (Cayman), Inc.'s PE ratio is 29.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concord Medical Services Holdings Ltd. is 0.30x versus 7.86x for WuXi Biologics (Cayman), Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCMConcord Medical Services Holdings Ltd.0.30x -- -- -- WXXWYWuXi Biologics (Cayman), Inc.7.86x 29.93x -- --
-
Which has Higher Returns CCM or YI?
111, Inc. has a net margin of -- compared to Concord Medical Services Holdings Ltd.'s net margin of -0.5%. Concord Medical Services Holdings Ltd.'s return on equity of -19.78% beat 111, Inc.'s return on equity of -26.11%.
Company Gross Margin Earnings Per Share Invested Capital CCMConcord Medical Services Holdings Ltd.-- -- $727.8M YI111, Inc.5.93% -$0.21 $59.5M -
What do Analysts Say About CCM or YI?
Concord Medical Services Holdings Ltd. has a consensus price target of --, signalling upside risk potential of 244.83%. On the other hand 111, Inc. has an analysts' consensus of -- which suggests that it could grow by 634%. Given that 111, Inc. has higher upside potential than Concord Medical Services Holdings Ltd., analysts believe 111, Inc. is more attractive than Concord Medical Services Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CCMConcord Medical Services Holdings Ltd.0 0 0 YI111, Inc.0 0 0 -
Is CCM or YI More Risky?
Concord Medical Services Holdings Ltd. has a beta of -1.213, which suggesting that the stock is 221.26% less volatile than S&P 500. In comparison 111, Inc. has a beta of 0.674, suggesting its less volatile than the S&P 500 by 32.648%.
-
Which is a Better Dividend Stock CCM or YI?
Concord Medical Services Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 111, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Concord Medical Services Holdings Ltd. pays -- of its earnings as a dividend. 111, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCM or YI?
Concord Medical Services Holdings Ltd. quarterly revenues are --, which are smaller than 111, Inc. quarterly revenues of $419.3M. Concord Medical Services Holdings Ltd.'s net income of -- is lower than 111, Inc.'s net income of -$2.1M. Notably, Concord Medical Services Holdings Ltd.'s price-to-earnings ratio is -- while 111, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concord Medical Services Holdings Ltd. is 0.30x versus 0.04x for 111, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCMConcord Medical Services Holdings Ltd.0.30x -- -- -- YI111, Inc.0.04x -- $419.3M -$2.1M
-
Which has Higher Returns CCM or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to Concord Medical Services Holdings Ltd.'s net margin of -30.98%. Concord Medical Services Holdings Ltd.'s return on equity of -19.78% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital CCMConcord Medical Services Holdings Ltd.-- -- $727.8M ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About CCM or ZLAB?
Concord Medical Services Holdings Ltd. has a consensus price target of --, signalling upside risk potential of 244.83%. On the other hand Zai Lab Ltd. has an analysts' consensus of $43.42 which suggests that it could grow by 116.67%. Given that Concord Medical Services Holdings Ltd. has higher upside potential than Zai Lab Ltd., analysts believe Concord Medical Services Holdings Ltd. is more attractive than Zai Lab Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CCMConcord Medical Services Holdings Ltd.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is CCM or ZLAB More Risky?
Concord Medical Services Holdings Ltd. has a beta of -1.213, which suggesting that the stock is 221.26% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.879, suggesting its less volatile than the S&P 500 by 12.141%.
-
Which is a Better Dividend Stock CCM or ZLAB?
Concord Medical Services Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Concord Medical Services Holdings Ltd. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCM or ZLAB?
Concord Medical Services Holdings Ltd. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Concord Medical Services Holdings Ltd.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, Concord Medical Services Holdings Ltd.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concord Medical Services Holdings Ltd. is 0.30x versus 4.87x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCMConcord Medical Services Holdings Ltd.0.30x -- -- -- ZLABZai Lab Ltd.4.87x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
